Overview

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Status:
Not yet recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous Non-Small Cell Lung Cancers

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hummingbird Bioscience

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Cetuximab
Docetaxel